Amylyx co-CEOs Justin Klee (L) and Joshua Cohen (Cody O'Loughlin/The New York Times; courtesy Amylyx)
EU committee likely to recommend against approving Amylyx ALS drug, company says
Amylyx Pharmaceuticals’ ALS drug is seemingly headed for a rockier path in the EU than it faced in the US and Canada.
The biotech announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
